In the presented study, patients who were treated with the highest doses of GCS (precisely, children newly diagnosed with JIA or patients admitted to the hospital because of the disease flare) had remarkably lower VE-cadherin levels than patients treated with biological agents, who mostly presented with the low disease activity and did not require GCS. Here, CDH5 is linked to juvenile idiopathic arthritis.